All In Biotech

Drug Trial Radar · NCT06058793

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

138

Actual

Start

Dec 13, 2023

Primary completion

Dec 12, 2025

Study completion Dec 12, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check participants' health and take note of any unwanted effects. The doctors also regularly check tumour size.

Conditions

  • Liposarcoma, Dedifferentiated

Interventions

  • BrigimadlinDrug

    Brigimadlin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment-emergent adverse events (TEAEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 during the entire treatment periodTime frame: up to 23 months
  2. Occurrence of TEAEs with Grade ≥3 according to CTCAE version 5 during the entire treatment periodTime frame: up to 23 months

Locations

56 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic-Arizona

    Phoenix, Arizona

  • Precision NextGen Oncology

    Beverly Hills, California

  • Sarcoma Oncology Center

    Santa Monica, California

  • University of California Los Angeles

    Santa Monica, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Mayo Clinic - Florida

    Jacksonville, Florida

  • University Cancer and Blood Center

    Athens, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Kansas Cancer Center

    Overland Park, Kansas

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • Northwell Health

    Lake Success, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Abramson Cancer Center at Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • West Cancer Center & Research Institute

    Germantown, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists Cancer Center

    Salt Lake City, Utah

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Medical Oncology Associates, P.S.

    Spokane, Washington

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Hospital Britanico de Buenos Aires

    CABA, Argentina

  • Sanatorio Finochietto

    CABA, Argentina

  • Hospital Italiano de Buenos Aires

    CABA, Argentina

  • Instituto Medico Especializado Alexander Fleming

    Ciudad Autonoma de Bs As, Argentina

  • Prince of Wales Hospital-Randwick-66496

    Randwick, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Pronutrir

    Fortaleza, Brazil

  • Hospital do Cancer de Londrina

    Londrina, Brazil

  • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia

    Santo André, Brazil

  • Hospital Sao Domingos

    São Luís, Brazil

  • H.S.J. Beneficência Portuguesa - São Paulo

    São Paulo, Brazil

  • Arthur J. E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.